Key Differences Summary# Conclusion# Liraglutide represents a meaningful advancement over exenatide across glycemic control (LEAD-6 and DURATION-6 head-to-head superiority), weight management (only agent with FDA obesity approval among the two), cardiovascular outcomes (LEADER superiority vs EXSCEL non-inferiority), and tolerability (less persistent nausea, no injection site nodules, minimal immunogenicity)
It manages hunger cues, allowing you to more easily maintain a calorie-restricted schedule
People with a body mass index (BMI) of 30 and above may qualify, or those with a BMI above 27 who also have certain comorbidities, provided they receive structured diet and lifestyle support
[DOI] [PubMed] [Google Scholar] [31].Ferreira RL, de Almeida SM, Bscolo FN, Santos AO, Camargo EE, Bone scintigraphy as an adjunct for the diagnosis of oral diseases, J
Notably, no cases of clinically significant hypoglycemia, medullary thyroid cancer, or C-cell hyperplasia were reported in published trial data
.png)
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
